Question explored with the scientific record
Is ozempic safe
The short version: Ozempic (semaglutide) works for weight and blood sugar, but its safety profile has real gaps that the evidence here does not fully close.
The evidence here is a mixed bag. The SUSTAIN-6 trial, funded by the manufacturer, showed a clear cardiovascular benefit: about 3 in 100 people on semaglutide had a heart attack, stroke, or died from heart disease, compared to about 4 in 100 on placebo over two years [3]. That is a real reduction. But the same trial also found a signal for diabetic retinopathy: 3.0% on semaglutide versus 1.8% on placebo, likely tied to rapid blood sugar drops [3, 8]. A case report linked semaglutide to acute pancreatitis in a patient with multiple risk factors [1], and another case described gallstone pancreatitis after weight loss [7]. Gastrointestinal side effects are common: nausea in about 30-38% of users, vomiting in 10-15%, and constipation in 16-22% [8]. About 5-13% of people stop the drug because of side effects [4].
The biggest problem is what the evidence does not cover. There is no long-term safety study here, no comparison of semaglutide users to truly untreated people over years. The cancer review [2] is largely neutral, but it is a review of conflicted literature, not a fresh trial. A 2025 study found that only 1.8% of patients got a complete pre-treatment evaluation for pancreatic and thyroid risks [5]. The drug costs up to $1,300 a month [6], and misuse for cosmetic weight loss is a documented concern [6].
| Outcome | Semaglutide | Placebo | Notes |
|---|---|---|---|
| Major cardiovascular events (2 years) | ~3.3% | ~4.4% | HR 0.74 [3] |
| Diabetic retinopathy (2 years) | 3.0% | 1.8% | Likely from rapid glucose drop [3] |
| Nausea | 30-38% | Lower | Most common side effect [8] |
| Discontinuation due to side effects | 5-13% | Lower | Across trials [4] |
My call: Ozempic has proven short-term benefits for weight and cardiovascular risk, but the evidence base is thin on long-term safety, especially for pancreatic and thyroid risks. The burden of proof has not been met for a drug you take for years. Confidence: moderate for short-term benefit, low for long-term safety.
Sources used 8
-
Semaglutide induced Pancreatitis
This case report discusses a 48-year-old male patient who developed acute pancreatitis after starting semaglutide, a glucagon-like peptide-1 receptor agonist, highlighting the potential risks associated with its use.
DOI: 10.36948/ijfmr.2024.v06i04.26238 -
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
A comprehensive review of clinical and preclinical evidence on GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide, retatrutide) and cancer, showing largely neutral to protective cancer risk signals in humans with obesity/diabetes and tumor-suppressive effects i…
DOI: 10.1172/jci194743 -
Safety of injectable semaglutide for type 2 diabetes
A narrative safety review of injectable semaglutide for type 2 diabetes, synthesizing safety data from the SUSTAIN programme and related analyses, highlighting overall good safety with gastrointestinal effects, potential renoprotection, a signal for diabetic retinopathy risk lik…
DOI: 10.1080/14740338.2020.1772230 -
Long-term Safety Profile of Semaglutide in the Management of Type 2 Diabetes and Obesity
Semaglutide shows overall long-term tolerability in type 2 diabetes and obesity, with dose-dependent gastrointestinal side effects and rare but serious risks like pancreatitis and retinopathy, underscoring the need for extended safety data.
DOI: 10.61173/rvr8p069 -
Evaluation of Pre-Treatment Assessment of Semaglutide Users: Balancing the Benefits of Weight Loss vs. Potential Health Consequences
A retrospective, single-center study at King Khalid University Hospital, Riyadh, Saudi Arabia, evaluating pretreatment assessments of semaglutide users for obesity, revealing a high burden of comorbidities and substantial gaps in comprehensive pretreatment screening, including m…
DOI: 10.3390/healthcare13151827 -
Therapeutic Boon or Hidden Bane? Semaglutide for Weight Loss in Non-diabetics
A narrative review concludes that semaglutide achieves substantial weight loss and cardiovascular benefits in nondiabetic patients, but high cost, gastrointestinal and rare serious side effects, and misuse risks require comprehensive obesity-care strategies.
DOI: 10.29328/journal.jcmhs.1001080 -
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
This case report describes alectinib-induced excessive weight gain in a young ALK+ NSCLC patient that was effectively reduced with semaglutide (GLP-1 receptor agonist), though weight rebounds occurred after discontinuation due to gallstone pancreatitis, highlighting potential, b…
DOI: 10.2147/LCTT.S549011 -
The Dual Faces of Semaglutide: A Comparative Analysis of Ozempic Side Effect Profiles in Western Populations and Saudi Arabia
A systematic review comparing semaglutide safety between Western and Saudi populations, revealing region-specific adverse-event patterns and implications for tailored monitoring and guidelines.
DOI: 10.59644/oagmr.4(1).212